Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | PDE5A | O76074 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014389 | 0.96 | POLB (0.53) | HSD11B1POLBSMN1; SMN2MAPTPDE5A | |
| SCHEMBL1015713 | 0.96 | HSD11B1 (0.53) | HSD11B1POLBPDE5A | |
| SCHEMBL1016067 | 0.89 | PDE5A (0.48) | HSD11B1PDE5A | |
| SCHEMBL1012298 | 0.81 | MERTK (0.49) | POLBSMN1; SMN2 | |
| SCHEMBL1014624 | 0.79 | HSD11B1 (0.62) | HSD11B1POLBSMN1; SMN2MAPT | |
| SCHEMBL1013801 | 0.78 | HSD11B1 (0.64) | HSD11B1POLBSMN1; SMN2MAPT | |
| SCHEMBL1014425 | 0.78 | HSD11B1 (0.61) | HSD11B1POLBSMN1; SMN2MAPT | |
| SCHEMBL1015182 | 0.78 | HSD11B1 (0.61) | HSD11B1POLBSMN1; SMN2MAPT | |
| SCHEMBL1013949 | 0.76 | POLB (0.59) | HSD11B1POLBSMN1; SMN2MAPTPIK3CA | |
| SCHEMBL1014805 | 0.75 | ALDH1A1 (0.55) | HSD11B1POLBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | HSD11B1 2/4885POLB 2006/4885SMN1; SMN2 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.